Attached files
| file | filename |
|---|---|
| EXCEL - IDEA: XBRL DOCUMENT - BIOMIMETIC THERAPEUTICS, INC. | Financial_Report.xls |
| 10-Q - 10-Q - BIOMIMETIC THERAPEUTICS, INC. | v311787_10q.htm |
| EX-31.2 - EXHIBIT 31.2 - BIOMIMETIC THERAPEUTICS, INC. | v311787_ex31-2.htm |
| EX-32.1 - EXHIBIT 32.1 - BIOMIMETIC THERAPEUTICS, INC. | v311787_ex32-1.htm |
| EX-31.1 - EXHIBIT 31.1 - BIOMIMETIC THERAPEUTICS, INC. | v311787_ex31-1.htm |
| EX-32.2 - EXHIBIT 32.2 - BIOMIMETIC THERAPEUTICS, INC. | v311787_ex32-2.htm |
EXHIBIT 10.1
2012 MANAGEMENT CASH INCENTIVE PLAN
Russ Pagano and **
Russ Pagano and ** shall each be provided the following milestone-based cash incentive bonus opportunities, totaling a maximum of up to $100,000:
| (1) | A single cash incentive bonus based upon the date of the ABG Approval (as defined below), in the amount of: |
| (a) | Eighty thousand dollars ($80,000); provided that ABG Approval occurs on or before **; or |
| (b) | Fifty thousand dollars ($50,000); provided that ABG Approval occurs after **, but on or before **; or |
| (c) | Twenty thousand dollars ($20,000); provided that ABG Approval occurs after **, but on or before **; |
wherein “ABG Approval” shall occur upon: (1) FDA Approval of Augment Bone Graft (“ABG”), (2) the approval by all requisite state governmental agencies that are required to sell ABG in at least **, and (3) filing for a manufacturer’s license in **l.
| (2) | Twenty thousand dollars ($20,000); provided that on or before ** BioMimetic receives regulatory marketing approval to begin selling Augment® Bone Graft in all major markets in the European Union (“EU”), and BioMimetic receives the $10 million milestone payment from Luitpold under the November 1, 2010 agreement between BioMimetic and Luitpold entitled Amendment No. 1 to Agreement Terminating Research, Development and Marketing Agreement. |
| ** | Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended, and has been filed separated with the Securities and Exchange Commission. |